The protein farnesyltransferase inhibitor tipifarnib as a new lead for the development of drugs against Chagas disease

被引：72

作者：

Hucke, O

Gelb, MH

Verlinde, CLMJ

Buckner, FS ^{[1
]}

机构：

[1] Univ Washington, Dept Med, Seattle, WA 98195 USA

[2] Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA

[3] Univ Washington, Dept Chem, Seattle, WA 98195 USA

[4] Univ Washington, Dept Biochem, Seattle, WA 98195 USA

[5] Univ Washington, Biomol Struct Ctr, Seattle, WA 98195 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 17期

关键词：

D O I：

10.1021/jm050441z

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Tipifarnib (R115777), an inhibitor of human protein farnesyltransferase (PFT), is shown to be a highly potent inhibitor of Trypanosoma cruzi growth (ED50 = 4 nM). Surprisingly, this is due to the inhibition of cytochrome P450 sterol 14-demethylase (CYP51, EC 1.14.13.70). Homology models of the T cruzi CYP51 were used for the prediction of the binding modes of the substrate lanosterol and of Tipifarnib, providing a basis for the design of derivatives with selectivity for TcCYP51 over human PFT.

引用

页码：5415 / 5418

页数：4

共 50 条

[21] Electrochemical studies of possible new drugs to treat Chagas disease
Arena, Alexander W.
Arrieta, Francisco E.
Papadopoulou, Maria
Smith, Diane K.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[22] Two approaches to discovering and developing new drugs for Chagas disease
McKerrow, J. H.
Doyle, P. S.
Engel, J. C.
Podust, L. M.
Robertson, S. A.
Ferreira, R.
Saxton, T.
Arkin, M.
Kerr, I. D.
Brinen, L. S.
Craik, C. S.
[J]. MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2009, 104 : 263 - 269
[23] Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
Alsina, M
Fonseca, R
Wilson, EF
Belle, AN
Gerbino, E
Price-Troska, T
Overton, RM
Ahmann, G
Bruzek, LM
Adjei, AA
Kaufmann, SH
Wright, JJ
Sullivan, D
Djulbegovic, B
Cantor, AB
Greipp, PR
Dalton, WS
Sebti, SM
[J]. BLOOD, 2004, 103 (09) : 3271 - 3277
[24] Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Salas, Cristian O.
Faundez, Mario
Morello, Antonio
Maya, Juan Diego
Tapia, Ricardo A.
[J]. CURRENT MEDICINAL CHEMISTRY, 2011, 18 (01) : 144 - 161
[25] Development policy of the World Health Organization against Chagas disease. Global Network for the elimination of Chagas disease
Vinas, Pedro Albajar
Pinto Dias, Joao Carlos
[J]. REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2008, 41 : 166 - 167
[26] Aim for the Readers! Bromodomains As New Targets Against Chagas' Disease
Lucia Alonso, Victoria
Emilio Tavernelli, Luis
Pezza, Alejandro
Cribb, Pamela
Ritagliati, Carla
Serra, Esteban
[J]. CURRENT MEDICINAL CHEMISTRY, 2019, 26 (36) : 6544 - 6563
[27] Advances in the treatment of Chagas disease: Promising new drugs, plants and targets
Garcia-Huertas, Paola
Cardona-Castro, Nora
[J]. BIOMEDICINE & PHARMACOTHERAPY, 2021, 142
[28] The urgent need to develop new drugs and tools for the treatment of Chagas disease
Munoz, Maria
Murcia, Laura
Segovia, Manuel
[J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (01) : 5 - 7
[29] Evidence that certain 8-aminoquinolines are potentially effective drugs against Chagas disease
Kinnamon, KE
Poon, BT
Hanson, WL
Waits, VB
[J]. ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1997, 91 (02): : 147 - 152
[30] MOLECULAR AND IMMUNOLOGICAL BASIS FOR THE DEVELOPMENT OF A VACCINE AGAINST CHAGAS-DISEASE
SEGURA, EL
CARDONI, RL
BUA, J
ROTTENBERG, ME
BONTEMPI, EJ
ESTEVA, MI
CARLOMAGNO, MA
DETITTO, EH
RUIZ, AM
[J]. MEDICINA-BUENOS AIRES, 1989, 49 (03) : 203 - 209

← 1 2 3 4 5 →